Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart Kupfer

Showing results (61-70 of 99) with videos related to

Pageof 10
Sort By:
European Heart Journal|October 21, 2025
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trialMartin S Maron, Juan Ramon Gimeno, Josef Veselka, et al.
European Heart Journal|March 24, 2022
Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trialScott D Solomon, Brian L Claggett, Zi Michael Miao, et al.
Circulation. Heart Failure|December 5, 2025
Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCMJuan Pablo Kaski, Paul F Kantor, Stephanie J Nakano, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|July 16, 2016
Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversionFaiez Zannad, Wendy Gattis Stough, Raymond J Lipicky, et al.
JAMA Cardiology|October 13, 2021
Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical TrialG Michael Felker, Scott D Solomon, Brian Claggett, et al.
European Heart Journal|June 8, 2022
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trialMarco Metra, Matteo Pagnesi, Brian L Claggett, et al.
Journal of Cardiac Failure|January 12, 2024
Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF StudyG Michael Felker, Scott D Solomon, Marco Metra, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCharles F Sherrod, Sara Saberi, Michael E Nassif, et al.
Journal of the American College of Cardiology|May 20, 2021
Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HFJohn R Teerlink, Rafael Diaz, G Michael Felker, et al.
ESC Heart Failure|February 19, 2026
Efficacy of aficamten according to geographic location of patients with hypertrophic obstructive cardiomyopathyCaroline J Coats, Theodore Abraham, Roberto Barriales-Villa, et al.
Pageof 10

Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
European Heart Journal|October 21, 2025
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trialMartin S Maron, Juan Ramon Gimeno, Josef Veselka, et al.
European Heart Journal|March 24, 2022
Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trialScott D Solomon, Brian L Claggett, Zi Michael Miao, et al.
Circulation. Heart Failure|December 5, 2025
Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCMJuan Pablo Kaski, Paul F Kantor, Stephanie J Nakano, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|July 16, 2016
Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversionFaiez Zannad, Wendy Gattis Stough, Raymond J Lipicky, et al.
JAMA Cardiology|October 13, 2021
Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical TrialG Michael Felker, Scott D Solomon, Brian Claggett, et al.
European Heart Journal|June 8, 2022
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trialMarco Metra, Matteo Pagnesi, Brian L Claggett, et al.
Journal of Cardiac Failure|January 12, 2024
Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF StudyG Michael Felker, Scott D Solomon, Marco Metra, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCharles F Sherrod, Sara Saberi, Michael E Nassif, et al.
Journal of the American College of Cardiology|May 20, 2021
Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HFJohn R Teerlink, Rafael Diaz, G Michael Felker, et al.
ESC Heart Failure|February 19, 2026
Efficacy of aficamten according to geographic location of patients with hypertrophic obstructive cardiomyopathyCaroline J Coats, Theodore Abraham, Roberto Barriales-Villa, et al.
Pageof 10